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Abstract
Background: Chronic inflammatory diseases including inflammatory bowel disease (IBD; Crohn's disease and 
ulcerative colitis), psoriasis and rheumatoid arthritis (RA) afflict millions of people worldwide, but their pathogenesis is 
still not well understood.
It is also not well known if distinct changes in gene expression characterize these diseases and if these patterns can
discriminate between diseased and control patients and/or stratify the disease. The main focus of our work was the
identification of novel markers that overlap among the 3 diseases or discriminate them from each other.
Methods: Diseased (n = 13, n = 15 and n = 12 in IBD, psoriasis and RA respectively) and healthy patients (n = 18) were 
recruited based on strict inclusion and exclusion criteria; peripheral blood samples were collected by clinicians (30 ml) 
in Venous Blood Vacuum Collection Tubes containing EDTA and peripheral blood mononuclear cells were separated by 
Ficoll gradient centrifugation. RNA was extracted using Trizol reagent. Gene expression data was obtained using 
TaqMan Low Density Array (TLDA) containing 96 genes that were selected by an algorithm and the statistical analyses 
were performed in Prism by using non-parametric Mann-Whitney U test (P-values < 0.05).
Results: Here we show that using a panel of 96 disease associated genes and measuring mRNA expression levels in 
peripheral blood derived mononuclear cells; we could identify disease-specific gene panels that separate each disease 
from healthy controls. In addition, a panel of five genes such as ADM, AQP9, CXCL2, IL10 and NAMPT discriminates 
between all samples from patients with chronic inflammation and healthy controls. We also found genes that stratify 
the diseases and separate different subtypes or different states of prognosis in each condition.
Conclusions: These findings and the identification of five universal markers of chronic inflammation suggest that 
these diseases have a common background in pathomechanism, but still can be separated by peripheral blood gene 
expression. Importantly, the identified genes can be associated with overlapping biological processes including 
changed inflammatory response. Gene panels based on such markers can play a major role in the development of 
personalized medicine, in monitoring disease progression and can lead to the identification of new potential drug 
targets in chronic inflammation.
Background
Chronic inflammatory diseases such as inflammatory
bowel disease (IBD; including Crohn's disease - CD and
ulcerative colitis - UC), psoriasis and rheumatoid arthritis
(RA) exist as a substantial burden in social and economic
terms worldwide. Despite the importance of these dis-
eases, it is still not clear if characteristic gene expression
signatures can discriminate this group of diseases from
healthy controls, the various diseases from each other or
whether it is possible to stratify the diseases based on
gene expression changes.
These chronic conditions have common features such
as the autoimmune origin, the frequent co-morbidity and
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Page 2 of 13a few genes such as IL10, IL23R, SLC22A4 and SLC22A5
that have been identified as contributors to their genetic
background [Table 1]. However their prevalence and the
tissues affected are clearly different.
RA is a systemic autoimmune disorder, with a preva-
lence between 0.5-1.0% [1], that causes inflammation and
tissue damage in joints and tendon sheaths. Psoriasis
which is a chronic disorder of the skin and joints where
the psoriatic plaques are areas of inflammation and
excessive skin production, affects approximately 2% of
the population only in the USA [2]. 1-2% of Western pop-
ulations suffer from IBD [3] in which the common fea-
tures are the inflammation of the intestines and the
autoimmune origin.
Global and selective gene expression analyses have
already been performed in order to gather hints on the
mechanisms of these medical conditions by using human
biopsy samples such as colon tissue in IBD [4]; skin tissue
in psoriasis [5] and synovial tissue biopsy in RA [6]. How-
ever peripheral blood is a more accessible source of cells
and may be easier to use for screening processes. Further-
more as circulating peripheral blood mononuclear cells
(PBMCs) are key cells of inflammation, it may also reflect
disease mechanisms.
In addition studies of gene expression profiling of
PMBCs may provide a more cost effective and less inva-
sive alternative to biopsy or invasive measurements [7].
Examples of the clinical implications of this approach
include the analysis of human breast cancer progression
[8] and PBMC profiles in RA, systemic lupus erythemato-
sus, type I diabetes and multiple sclerosis [9].
It appears therefore that gene expression profiling from
PBMCs is a validated tool for discovery and also may be
used to explore the pathogenetic background of these
medical conditions [10-12]. However comparative studies
on the existence of distinct and overlapping gene expres-
sion patterns are lacking. We sought to fill this gap by car-
rying out a comparative analysis of peripheral gene
expression patterns of a panel containing 96 genes in var-
ious chronic inflammatory diseases and healthy controls.
Methods
Patient recruitment
The Research Ethics Committee of University of Debre-
cen Medical and Health Science Center approved the
Table 1: Known SNP - disease associations
Gene IBD Psoriasis Rheumatoid arthritis
ADAM33 NA rs512625 PMID: 18560587 NA
IL10 rs3024505 PMID: 18836448 NA rs1800896 PMID: 18615156
IL13 NA rs1800925 PMID: 19554022 NA
IL23R rs2201841 PMID: 18338763 rs11209026 PMID: 18369459 NA
IL4 rs2243250 PMID: 18064451 NA NA
IL8 NA NA PMID: 18799095
PADI4 NA NA rs2240340 PMID: 12833157
PTGS2 rs20432 PMID: 16273614 NA rs5275 PMID: 18381795
PTPN22 NA rs1217414 PMID: 18341666 rs2476601 PMID: 18466513
SLC22A4 rs3792876 PMID: 17476680 rs11568506 PMID: 18614543 rs3792876 PMID: 15107849
SLC22A5 rs3792876 PMID: 17476680 rs2631367 PMID: 16255050 rs2631367 PMID: 15107849
Known associations between single nucleotide polymorphisms and chronic inflammatory diseases are shown in the table with SNP ID and 
PMID number referring to the publication that documents the association. NA means there is no documented association on SNP level. Bold 
cells mean we could detect the association in our study between that specific disease and healthy controls.
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Page 3 of 13clinical protocol and the study that were in compliance
with the Helsinki Declaration. Signed informed consent
was obtained from all healthy and diseased individuals
who provided blood sample. Inclusion and exclusion cri-
teria were developed using the best evidence currently
available. Online supplement is provided for additional
information about inclusion and exclusion criteria [Addi-
tional File 1: Figure S2].
The study included 13 patients with IBD; 15 with psori-
asis and 12 with RA, all of whom had active disease and
were medication-free at the time of blood draw [Table 2].
Blood was also obtained from a group of healthy control
individuals (18 patients) that did not show significant dif-
ferences compared to the diseased groups regarding age.
After the subjects fasted overnight for 12 hours, all of the
blood samples were obtained locally between 8:00 AM
and 9:00 AM; and were processed within one hour after
sample collection.
Peripheral blood mononuclear cell collection and RNA 
processing
Venous peripheral blood samples were collected by clini-
cians (30 ml) in Venous Blood Vacuum Collection Tubes
containing EDTA (BD Vacutainer K2E). PBMCs were
separated by Ficoll gradient centrifugation.
Total RNA was extracted from PBMCs using Trizol
reagent (Invitrogen), according to the manufacturer's
protocol. RNA quality and quantity were checked on
NanoDrop and Agilent Bioanalyser 2100 (Agilent Tech-
nologies).
TaqMan mRNA analysis by RT-QPCR
Gene expression data was obtained using TaqMan Low
Density Array (TLDA) (Applied Biosystems) which is a
384-well micro fluidic card that enables to perform 384
simultaneous real-time PCR runs and which has been
used for gene expression profiling in several studies
[13,14]. This low- to medium- throughput micro fluidic
card allows for 2 samples to be run in parallel against 96
TaqMan® Gene Expression Assay targets that are pre-
loaded into each of the wells on the card. cDNA was gen-
erated with High Capacity cDNA Reverse Transcription
Kit according to manufacturer's protocol. 2 micrograms
of RNA were used per sample in the RT-PCR runs. 400 ng
(4 μl) cDNA was used in each sample. 196 μl nuclease-
free water and 200 μl 2× TaqMan Universal PCR Master
Mix (Applied Biosystems) were added for the Real-Time
Quantitative PCR measurements. This mixture was then
equally divided over four sample-loading ports of the
TLDA, each connected to one set of the 96 genes of inter-
est. The arrays were centrifuged once (1', 1300 RPM on
room temperature) to equally distribute the sample over
the wells. Subsequently, the card was sealed to prevent an
exchange between wells. RT-QPCR amplification was
performed using an Applied Biosystems Prism 7900HT
sequence detection system with the following thermal
Table 2: Patient parameters
Disease Status Control IBD Psoriasis Rheumatoid 
arthritis
n 18 13 15 12
Sex (male/female) 8/10 4/9 5/10 2/10
Age (years) 40.07 ± 21.3 27.92 ± 8.49 30.53 ± 9.3 45.83 ± 18.24
Clinical subtype NA CD/UC 8/4 Arthritis positive/
negative 4/11
Bone erosion 
positive/negative 
4/8
CDAI UCDAI PASI DAS28
Clinical severity NA 270.4 ± 67.18 8 ± 1.2 27.47 ± 9.62 6.12 ± 1.05
124-365 6-9 15-48 4.07-7.56
Definition of abbreviations: IBD = Inflammatory bowel disease, CD = Crohn's Disease, CDAI = Crohn's Disease Activity Index, UC = Ulcerative 
colitis, UC DAI = Ulcerative Colitis Disease Activity Index, PASI = Psoriasis Area Severity Index, DAS28 = Disease Activity Score 28, NA = non 
available. Data are presented as mean ± SD; also range in Clinical Severity.
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Page 4 of 13cycler conditions: 2 min at 50°C and 10 min at 94.5°C, fol-
lowed by 40 cycles of 30 s at 97°C and 1 min at 59.7°C.
Gene List Selection Process
A database containing 400 genes which are associated
with the 3 chronic inflammatory diseases and inflamma-
tion was constructed by using the data derived from the
Human Genome Navigator that lists all the genes related
to a specific disease and the evidence the relation is based
on; the current medical literature and international data-
bases (e.g. OMIM, Entrez Gene). Genes were also
selected from genome-wide association studies as well as
microarray analyses focusing on skin biopsy in psoriasis,
colon biopsy in IBD and synovial fluid in RA. (Figure 1)
In the second step, genes were put in order by using a
score list that was based on the number of publications
mentioning the disease-gene association, relation to
other diseases and expected expression in PBMC accord-
ing to previous studies and our pilot experiment in which
we analyzed selected genes in PBMC samples through
individual RT-QPCR assays. This selection process
resulted in 150 genes.
In the third step, genes that did not show expression
(missing signal in QPCR measurements) in the pilot
study were removed, leading to a final list of 96 genes
Additional File 1: Figure S1.
Statistical Analyses
Relative gene expression levels of each gene were calcu-
lated by comparative Ct method and results were normal-
ized to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) expression for each sample. Statistical analyses
of the normalized gene expression data were performed
in Prism (GraphPad). Due to the fact that our data did not
follow normal distributions, the gene expression in
groups with different numbers of samples was compared
separately using the non-parametric Mann-Whitney U
test. P-values < 0.05 were considered to be statistically
significant. This method that does not include correction
for multiple comparisons is widely used in the analysis of
TLDA data [15,13] and is explained in details in [16].
Gene interactions were analyzed by using the Direct
Interactions and Biological Processes functions of Gene-
Spring GX (Agilent Technologies).
Principal component analysis (PCA), a standard, non-
parametric tool that reduces a complex data set to a lower
dimension, was used in order to reveal the internal struc-
ture of the data sets and to project the differences
between diseased and healthy groups based on each set of
significantly changing genes.
Results
Identification of gene panels discriminating chronic 
inflammatory disease patients from healthy controls
A panel of 96 genes has been selected by the algorithm
depicted on Figure 1. Patients were recruited and PBMC
gene expression was determined as described in Materi-
als and Methods. When we compared the gene expres-
sion results we have found 53 genes that show significant
differences between diseased and healthy samples. First,
we looked at the gene panels that differentiate each dis-
ease from the set of control samples. Altogether 25 genes
show significant differences between IBD; 16 genes
between psoriasis; 33 genes between RA and controls
(Figure 2a-c). Principal component analysis of these gene
sets also separates the different groups of samples. In
order to get hints of the complex transcriptional basis of
inflammatory diseases and to find potential targets that
might play a role in the pathogenesis of the conditions,
the interaction among multiple genes needs to be
revealed. Gene interaction analyses highlighted IFNG,
IL4, IL10, MMP9 and TIMP1 in IBD; IL10, IL13 and
PTGS2 in psoriasis; IL8, IL10 and PTGS2 in RA. These
genes had the most direct interactions that might reveal
their key role in the pathogenetic background of the dis-
eases. Gene interaction analysis on each set of genes is
provided in the supplement material Additional File 1:
Figure S3-5.
Gene sets showing overlapping or differential expression
In order to analyze the gene expression patterns of these
conditions, first we created a Venn diagram highlighting
those genes that differentiate between a disease and the
set of control samples (Figure 3a).
Figure 1 Flowchart of gene selection process. A flow chart of the 
gene selection process shows the steps through which we chose the 
final 96 genes out of the database containing 400 genes.
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identification of a network that highlights the genes with
the most interactions such as CCL5, IFNG, IL4, IL8, IL10,
IL13, MMP9, PTGS2 and TIMP1 (Figure 3b) clearly
showing that not only individual genes but entire net-
works are impacted and hence can be identified.
Although there are genes that showed disease specific
signatures, all of these genes showing significant differ-
ences between diseased and healthy samples form a net-
work which might represent the common background of
the pathogenesis of this type of inflammation.
As the next step in our analysis all the significantly
changing genes were assigned to functional categories
that were created based on EASE, the Expression Analy-
sis Systematic Explorer that provides statistical methods
for discovering biological themes within gene lists [17].
Genes were grouped into inflammatory response; cell
growth and maintenance; proteolysis; metabolism and
unclassified (including genes in unique categories or
genes without categories) categories with 21, 11, 7, 9 and
7 genes respectively. In order to illustrate the similarities
in the pathogenetic background of these diseases, the
functional categories, the number of genes and the dis-
ease gene panels are visualized. It shows that there are
similar number of genes in the same functional categories
in each of the diseases, though the number of unique
genes (11 in IBD, 6 in psoriasis and 21 in RA) separating
only a disease from the control group is also high (Figure
4).
Diseases subtype stratification by differentially expressed 
genes
We also sought to identify potential markers that differ-
entiate between distinct subtypes or states of prognosis in
each of the three diseases to stratify the disease based on
gene expression patterns (Figure 5). Analyses of individ-
ual genes are provided in the supplement material Addi-
tional File 1: Figure S7-9.
Figure 2 Fold changes of genes differentiating between diseased and control samples. Fold change values of genes, showing statistically sig-
nificant (Mann-Whitney U test) differential expression between diseased and control patients, were generated from RT-QPCR measurements and rep-
resent the difference of the means of the diseased and control groups. Principal component analysis was performed and separates the two groups of 
samples. 2a represents the IBD, 2b the psoriasis and 2c the RA gene panel.
Mesko et al. BMC Medical Genomics 2010, 3:15
http://www.biomedcentral.com/1755-8794/3/15
Page 6 of 13Regarding IBD, ADAM10, CUGBP1, CUGBP2, DUSP1,
ETS2, FOS, IL6, IL18 and PGRMC1 show significantly
higher expression levels in patients with CD compared to
patients with UC (Figure 5a).
In psoriasis, CCL4, GZMK and KLRF1 show signifi-
cantly higher, while ADM, ANXA3, IL4, MMP9 and
OLR1 show significantly lower expression levels in
patients with arthritis negative psoriasis compared to
patients with symptoms of arthritis (Figure 5b).
HBB and PADI4 show lower; GZMK shows higher
expression in RA patients with bone erosions confirmed
with Magnetic Resonance Imaging compared to those
without such symptoms (Figure 5c).
Peripheral blood derived universal markers of chronic 
inflammation
Importantly, we have identified five genes, ADM, AQP9,
CXCL2, IL10 and NAMPT that show significant differ-
ences in expression levels between all the three condi-
tions and control samples (Figure 6). These genes might
be considered universal markers of chronic inflammation
in PBMCs. Regarding pathway analysis that features the
biological processes the genes are associated with; IL10
has the highest number of related biological processes
(over 20) including lymphocyte, T and B cell prolifera-
tion, interleukin production and macrophage activation.
ADM is related to 10 processes such as activation of
MAPK-activity and interleukin-6 production; while
AQP9, CXCL2 and NAMPT are only associated with a
single process, urea transport, interleukin-18 production
and neutrophil apoptosis, respectively (Figure 7).
We also determined the number of diseased patients
with gene expression levels above the range of the mean +
SD or 2 SD of control samples. Additional File 1: Figure
S6.
Discussion
It is of critical importance to identify new biomarkers and
hints of mechanisms of disease states and disease pro-
gression in illnesses affecting large populations such as
chronic inflammatory diseases in order to personalize
treatment and accurately monitor disease progression.
Methods based on genomic approaches and amongst
them global gene expression profiles play an increasing
role in such efforts.
The pathomechanism of these chronic inflammatory
diseases has been examined at different levels including
cell cultures, animal models and clinical samples. Impor-
tantly, as the molecular signature of disease across tissues
is overall more prominent than the signature of tissue
expression across diseases [18], there is good reason to
believe one can detect disease-specific gene expression
signatures in PBMC samples which are easy-to-access.
There have been studies analyzing the gene expression
patterns of these diseases in PBMC samples which led to
the identification of genes, which we also found to be sig-
nificantly different between disease and control patients.
Examples include PTGS2 in psoriasis [10]; PTPN22 in
RA [19] and GZMK in IBD [12]. Other groups compared
Figure 3 Genes separating chronic inflammatory diseases from controls. (a) Venn diagram shows all of those genes that show significant differ-
ences between each disease group and control samples. Each set contains genes that separate control samples only from the particular disease or 
diseases. Underlined genes were down-regulated compared to healthy controls. (b) Gene interaction analysis in GeneSpring GX in Direct Interactions 
mode highlights 28 genes that have direct interactions with each other while 25 genes have no direct interactions. Genes with the highest number 
of interactions are shown in extended size. Cyclooxygenase 2 enzyme is located in the middle of this pathway network. The genes that showed sig-
nificant differences between one of the diseased groups and healthy controls have color codes in which blue represents RA, green represents IBD and 
red codes for psoriasis-related genes.
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Figure 4 Functional categorization of significantly changing genes. We found 53 genes that show significantly differences between chronic in-
flammatory diseases and control samples. These genes were grouped into functional categories made by EASE. Genes were grouped in the category 
that had the highest relevance according to the EASE software. Colors represent disease groups. The size of the diagrams correlates with the number 
of genes in each set. Overlapping sets of genes are shown as overlapping diagrams.
Figure 5 Correlation between gene expression levels and clinical parameters. Normalized mRNA levels of genes showing significant differences 
between patients with (a) Crohn's disease and Ulcerative colitis; (b) psoriasis patients with and without arthritis; (c) RA patients with and without MR-
confirmed bone erosion were generated from RT-QPCR measurements and represent the means of the expression levels of the diseased and control 
groups.
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arthritis and spondyloarthropathy [20] or psoriatic
arthritis, RA and spondyloarthropathy [21], but such an
extended number of genes have not yet been found in
peripheral blood. Importantly the gene expression pro-
files of RA, IBD and psoriasis have not been compared
previously. We tried to fill this gap with our study and
identify markers of chronic inflammation that overlap
among the 3 conditions and also ones that discriminate
them from each other.
It should be noted though gene expression analyses of
these diseases provide little insight into the pathomecha-
nisms of the disease simply because it is impossible to
sort out what is cause and what is consequence. However
it can still provide hints or clues about the potential path-
ways affected. Therefore such datasets, although indi-
rectly, can form the basis of more mechanistic studies.
This is why we have carried out and presented the gene
interaction analyses of the genes identified and linked to
the different diseases. Significantly the existence of over-
lapping gene sets suggests that there are common path-
ways impacted among the studied diseases. A common
characteristic of all diseases is an altered inflammatory
response.
In addition, genetic association studies have already
identified SNPs linked to these diseases. A comparison of
our dataset to these can provide further support to those
findings [Table 1].
Several of the now identified differentially expressed
genes have been linked to the studied diseases although
either at a different level or different model. Regarding
the IBD gene panel, OLR1/LOX1 [22] and CCR1 [23]
both have immune response function and are expressed
in human intestinal cells. The homophilic ligation of
Figure 6 Peripheral blood derived universal markers of chronic inflammation. Normalized mRNA levels of genes (with SD) showing significant 
differences between all the samples of chronic inflammatory diseases and healthy controls were generated from RT-QPCR measurements.
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leads to the inhibition of a range of T-cell functions there-
fore it might be a new potential therapeutic target in the
treatment of IBD [24]. MMP9, a gelatinase, that showed a
7-fold up-regulation in diseased samples in our study is
an important mediator of tissue injury in colitis and is up-
regulated in sputum samples of CD patients [25]. Garg et
al. suggested that developing strategies to block MMP-9
activity in the gut might be of benefit to IBD [26]. TIMP1
is a natural inhibitor of matrix metalloproteinases
(MMPs) and might be considered a potential drug target.
The DNA methylation of IFNG that regulates immune
response was analyzed within the mucosal compartment
in both normal and IBD populations [27]. PTGS2/COX2
is related to IBD expression level in colon biopsy [28].
ABCA1, BASP1, GZMK, HBB, SEC14L1, THEM2 and
TNFAIP6 have never been associated with IBD; therefore
further analyses should be carried out.
In the psoriasis panel, CCR1 that plays a role in inflam-
matory response is associated with psoriasis via the anal-
ysis of skin lesion samples [29]. Koczan et al. identified
pairs of genes such as PTGS2/COX2 and NR1D2 which
allowed an accuracy of disease stage prediction of 86%,
based on gene expression patterns [10]. ADORA2B,
IFRD1, ITGA2B, MAP4K1, PADI4, PDE4A, SEC14L1
and TREM1 have no documented association with psori-
asis yet. Therefore these are candidates for further SNP/
genetic association or mechanistic studies.
Regarding the significantly changing genes in RA sam-
ples, IL8 is related to RA based on expression [30]. Van
Der Voort et al. demonstrated that the expression of
ADAM10 is strongly enhanced in RA synovia [31]. CCL4
was expressed in PBMC [30] and CCL5 showed high
serum levels [32]. Kehlen et al. found up-regulation of
TNFAIP6 in fibroblast-like synoviocytes of patients with
RA [33]. HMGB1 [34] and PLCB1 [35] only showed dif-
Figure 7 Pathway analysis of universal markers of chronic inflammation. Pathway analysis was carried out with GeneSpring GX Biological Pro-
cesses mode that revealed all the biological processes the genes are related to. Circles represent the 5 genes; deltoids represent biological processes.
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mRNA levels in PBMC samples from RA patients were
within the normal range or below normal [36]. ADAM12,
ADAM33, ADORA2B, AKT3, ANXA3, CDKN1C,
CTSL1, CUGBP1, CUGBP2, CYP51A1, FGL2, HBB,
HSP90AA1, KLRF1, NR1D2, SLC33A1 and THEM2 have
no evidence of association with RA and should further be
studied.
Gene expression profiling may allow early diagnosis,
aid in identifying prognosis or subtypes. We found genes
that differentiate between CD and UC in IBD of which
some have already been associated with the disease but at
a different level or in a different tissue. Alexander et al.
reported that the expression level of FOS was two- to
threefold higher in involved than in uninvolved areas of
the colons of two UC patients [37]. van der Pouw Kraan
at el. found that ETS2 may be an important transcription
factor driving inflammation in acute as well as chronic
inflammatory diseases such as IBD [38]. As oppose to
UC, IL-18 may serve as indicators of acute phase reactiv-
ity in CD, according to Haas et al. [39], that correlates
with our findings. Mitsuyama et al. suggested that IL-6
trans-signaling may play role in the development of IBD
and imply the possibility of a selective therapeutic strat-
egy to target this signaling [40].
A gene panel containing 8 genes shows significant dif-
ferences between patients with and without arthritis in
psoriasis. Hitchon et al. described that MMPs, especially
MMP2 and MMP9, have been implicated in several fea-
tures of inflammatory arthritis including angiogenesis
and bone erosions [41]. Partsch et al. measured the pro-
tein level of IL4 in synovial fluid of patients with psoriatic
arthritis (PsA) [42].
Another gene set including HBB, GZMK and PADI4
separates different states of prognosis in RA regarding
MR-confirmed bone erosion. In RA, PADI4 is a target of
autoantibodies; and its increased expression in synovia of
RA patients [43], also its relation to the disease at SNP
level have already been confirmed [44]. Osteoclasts are
shown to be mainly involved in the bone-destruction of
RA which may indicate further studies regarding the role
of PADI4 in bone erosion.
We consider a key aspect of our work is the identifica-
tion of five genes including ADM, AQP9, CXCL2, IL10
and NAMPT that differentiate between samples from
patients with chronic inflammation and healthy controls.
ADM that plays role in response to wounding is found to
be distributed on the surface of the human colonic
mucosa [45] and the plasma level of ADM in RA patients
was significantly higher compared to healthy controls in
synovial tissue [46]. CXCL2 that has function in immune
response is over-expressed in osteoarthritis fibroblasts
rather than rheumatoid fibroblasts [47], up-regulated in
psoriatic epidermis [48], and also in epithelial tissue [49].
IL10 is expressed in PBMCs of psoriasis [50], RA [51] and
IBD patients [52]. The expression of NAMPT which is a
pre-B cell-enhancing factor is increased in colonic biopsy
specimens of IBD patients compared to healthy controls
[53], it is also up-regulated in plasma and synovial fluid of
RA patients [54]; and in PBMC of psoriasis in the dis-
eased stage [10]. AQP9 that has an activity in immune
response has never been associated with any of these
medical conditions.
These genes might serve as universal markers of
chronic inflammation. As expected, IL10 seems to be the
key gene in this network regarding biological processes
(Figure 3b). As the number of biological processes related
to ADM is relatively high and it has no direct interactions
with the genes we examined, there might be other poten-
tial markers that play role in the pathomechanism of the
conditions we analyzed that also have similar pathways or
targets as ADM. Chronic inflammatory and autoimmune
diseases share a number of phenotypic and genetic char-
acteristics suggesting common etiological pathways or
pathomechanisms. Becker et al. used meta-analyses of
whole-genome scans and found non-random clustering
of disease susceptibility loci for autoimmune diseases
[55]. Our results may suggest that all of the chronic
inflammatory conditions we analyzed share similar
pathogenetic background as reflected by peripheral gene
expression.
Personalized medicine is becoming an integral part of
healthcare and the key challenge is to establish a strategic
focus on biomarker-based clinical tests. Non-invasive or
minimally invasive diagnostic tests present less danger to
a patient than invasive tests such as biopsies; and can help
clinicians by providing them with valuable information in
decision-making. A biomarker assay based on the gene
panels described above might save time by reducing a list
of preliminary disease impressions to a definitive diagno-
sis. The evaluation of these results and the identification
of genes with altered expression or marker genes could
also be potential targets for novel and more effective
therapies and may lead to important insights into the
pathogenesis of chronic inflammatory diseases. It might
also have benefits to look at the identified gene panels in
terms of SNPs in order to identify potential genetic
changes associated with these medical conditions. Such
novel and known biomarkers or a panel of such markers
can play a major role in the development of personalized
medicine.
Conclusion
Our results suggest that IBD, psoriasis and rheumatoid
arthritis have common pathogenetic background and
gene expression profiling from peripheral blood might
reveal novel targets and pathways affected by these dis-
eases.
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Abbreviations
ABCA1: ATP-binding cassette, sub-family A, member 1; ADAM10: ADAM metal-
lopeptidase domain 10; ADAM12: ADAM metallopeptidase domain 12;
ADAM33: ADAM metallopeptidase domain 33; ADM: Adrenomedullin;
ADORA2B: adenosine A2b receptor; AKT3: v-akt murine thymoma viral onco-
gene homolog 3; ANXA3: annexin A3; AQP9: Aquaporin 9; BASP1: brain abun-
dant, membrane attached signal protein 1; CCL4: chemokine (C-C motif )
ligand 4; CCL5: chemokine (C-C motif ) ligand 5; CCR1: chemokine (C-C motif )
receptor 1; CDKN1C: cyclin-dependent kinase inhibitor 1C; CEACAM1: carcino-
embryonic antigen-related cell adhesion molecule 1; CTSL1: cathepsin L1;
CUGBP1: CUG triplet repeat, RNA binding protein 1; CUGBP2: CUG triplet
repeat, RNA binding protein 2; CXCL2: chemokine (C-X-C motif ) ligand 2;
CYP1B1: cytochrome P450, family 1, subfamily B, polypeptide 1; CYP51A1: cyto-
chrome P450, family 51, subfamily A, polypeptide 1; FGL2: fibrinogen-like 2; GK:
glycerol kinase; GZMK: granzyme K; HBB: hemoglobin, beta; HSP90AA1: heat
shock protein 90 kDa alpha (cytosolic), class A member 1; IBD: Inflammatory
bowel disease; IFNG: interferon gamma; IFRD1: interferon-related developmen-
tal regulator 1; IL10: Interleukin 10; IL13: Interleukin 13; IL23R: Interleukin 23
receptor; IL4: Interleukin 4; IL8: Interleukin 8; ITGA2B: integrin, alpha 2b; KLRF1:
killer cell lectin-like receptor subfamily F, member 1; MAP4K1: mitogen-acti-
vated protein kinase 1; MMP9: matrix metallopeptidase 9; NAMPT: nicotin-
amide phosphoribosyltransferase; NR1D2: nuclear receptor subfamily 1, group
D, member 2; OLR1: oxidized low density lipoprotein receptor 1; PADI4: pepti-
dyl arginine deiminase, type IV; PBMC: Peripheral Blood Mononuclear Cells;
PDE4A: cAMP-specific phosphodiesterase 4D; PLCB1: phospholipase C, beta 1
(phosphoinositide-specific); PTGS2: prostaglandin-endoperoxide synthase 2
(prostaglandin G/H synthase and cyclooxygenase); PTPN22: protein tyrosine
phosphatase, non-receptor type 22 (lymphoid); QPCR: Quantitative poly-
merase chain reaction; RA: Rheumatoid arthritis; SEC14L1: SEC14-like 1 (S. cere-
visiae); SLC22A4: solute carrier family 22 member 4; SLC22A5: solute carrier
family 22 member 5; SLC33A1: solute carrier family 33 member 1; THEM2: acyl-
CoA thioesterase 13; TIMP1: TIMP metallopeptidase inhibitor 1; TLDA: Taqman
Low Density Array; TNFAIP6: tumor necrosis factor, alpha-induced protein 6;
TREM1: triggering receptor expressed on myeloid cells 1
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
B.M designed and carried out experiments, analyzed data and wrote the paper.
S.P. designed and carried out experiments and analyzed the data, A.S., Z.S., K.P.
and M.P. determined patient inclusion and exclusion criteria, carried out
patient recruitment and collection. L.N. directed research, designed experi-
ments, analyzed the data and wrote the paper.
Acknowledgements
The authors are indebted to Ms. Zsuzsa Bodnar for clinical coordination. They 
also thank Dr Arpad Lanyi and the members of the Nagy laboratory for their 
comments. The authors would like to express their thanks for the expert tech-
nical assistance of Ms. Ibolya Furtos.
L.N is an International Scholar of HHMI and holds a Wellcome Trust Senior 
Research Fellowship in Biomedical Sciences, this work was also supported by 
grants from the National Office for Research and Technology (NKFP 1/007/01, 
NKFP 1A/008/04), from the National Research Fund (NI 67877) and a grant from 
the Hungarian Ministry of Health (ETT 294-07) to L.N.
Author Details
1Department of Biochemistry and Molecular Biology, University of Debrecen, 
Debrecen, Hungary, 2Apoptosis and Genomics Research Group of the 
Hungarian Academy of Sciences, Research Center for Molecular Medicine, 
Medical and Health Science Center, University of Debrecen, Debrecen, 
Hungary, 3Department of Dermatology, Medical and Health Science Center, 
University of Debrecen, Debrecen, Hungary, 4Clinical Genomics Center, 
Medical and Health Science Center, University of Debrecen, Debrecen, 
Hungary, 5Department of Rheumatology, Institute of Medicine, University of 
Debrecen, Medical and Health Science Center, Debrecen, Hungary and 62nd 
Department of Medicine, University of Debrecen, Medical and Health Science 
Center, Debrecen, Hungary
References
1. Silman AJ, Pearson JE: Epidemiology and genetics of rheumatoid 
arthritis.  Arthritis Res 2002, 4(Suppl 3):S265-272.
2. Langley RG, Krueger GG, Griffiths CE: Psoriasis: epidemiology, clinical 
features, and quality of life.  Ann Rheum Dis 2005, 64(Suppl 2):ii18-23. 
discussion ii24-15
3. Loftus EV Jr: Clinical epidemiology of inflammatory bowel disease: 
Incidence, prevalence, and environmental influences.  Gastroenterology 
2004, 126(6):1504-1517.
4. Wu F, Dassopoulos T, Cope L, Maitra A, Brant SR, Harris ML, Bayless TM, 
Parmigiani G, Chakravarti S: Genome-wide gene expression differences 
in Crohn's disease and ulcerative colitis from endoscopic pinch 
biopsies: insights into distinctive pathogenesis.  Inflamm Bowel Dis 
2007, 13(7):807-821.
5. Nomura I, Gao B, Boguniewicz M, Darst MA, Travers JB, Leung DY: Distinct 
patterns of gene expression in the skin lesions of atopic dermatitis and 
psoriasis: a gene microarray analysis.  J Allergy Clin Immunol 2003, 
112(6):1195-1202.
6. van Baarsen LG, Wijbrandts CA, Timmer TC, Pouw Kraan TC van der, Tak PP, 
Verweij CL: Synovial tissue heterogeneity in rheumatoid arthritis in 
relationship to disease activity and biomarkers in peripheral blood.  
Arthritis Rheum 2010 in press.
7. Aziz H, Zaas A, Ginsburg GS: Peripheral blood gene expression profiling 
for cardiovascular disease assessment.  Genomic Med 2007, 1(3-
4):105-112.
8. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, Payette T, 
Pistone M, Stecker K, Zhang BM, et al.: Gene expression profiles of human 
breast cancer progression.  Proc Natl Acad Sci USA 2003, 
100(10):5974-5979.
9. Maas K, Chan S, Parker J, Slater A, Moore J, Olsen N, Aune TM: Cutting 
edge: molecular portrait of human autoimmune disease.  J Immunol 
2002, 169(1):5-9.
10. Koczan D, Guthke R, Thiesen HJ, Ibrahim SM, Kundt G, Krentz H, Gross G, 
Kunz M: Gene expression profiling of peripheral blood mononuclear 
leukocytes from psoriasis patients identifies new immune regulatory 
molecules.  Eur J Dermatol 2005, 15(4):251-257.
11. Junta CM, Sandrin-Garcia P, Fachin-Saltoratto AL, Mello SS, Oliveira RD, 
Rassi DM, Giuliatti S, Sakamoto-Hojo ET, Louzada-Junior P, Donadi EA, et 
al.: Differential gene expression of peripheral blood mononuclear cells 
from rheumatoid arthritis patients may discriminate immunogenetic, 
pathogenic and treatment features.  Immunology 2009, 127(3):365-372.
12. Burczynski ME, Peterson RL, Twine NC, Zuberek KA, Brodeur BJ, Casciotti L, 
Maganti V, Reddy PS, Strahs A, Immermann F, et al.: Molecular 
classification of Crohn's disease and ulcerative colitis patients using 
transcriptional profiles in peripheral blood mononuclear cells.  J Mol 
Diagn 2006, 8(1):51-61.
Additional file 1 List of genes, gene interaction analyses and detailed 
gene expression data. • Figure S1) List of genes that were measured on 
the TaqMan Low Density Arrays. • Figure S2) Inclusion and exclusion criteria 
of diseased patients and healthy controls. • Figure S3) Gene interaction 
analysis ("Cell mode" in GeneSpring GX) of the genes differentiating 
between IBD and controls. • Figure S4) Gene interaction analysis ("Cell 
mode" in GeneSpring GX) of the genes differentiating between psoriasis 
and controls. • Figure S5) Gene interaction analysis ("Cell mode" in Gene-
Spring GX) of the genes differentiating between RA and controls. • Figure 
S6) Number of diseased patients with gene expression levels outside the 
range of the mean ± SD or 2 SD in control sample. Based on Figure 6. • Fig-
ure S7) Stratifying IBD: The results of the RT-QPCR measurements for each 
gene that showed significant differences between Crohn's disease vs Ulcer-
ative colitis patients. • Figure S8) Stratifying Psoriasis: The results of the RT-
QPCR measurements for each gene that showed significant differences 
between arthritis negative vs positive forms. • Figure S9) Stratifying RA: The 
results of the RT-QPCR measurements for each gene that showed signifi-
cant differences between patients with MRI confirmed bone erosion vs 
patients without bone erosion.
Received: 24 November 2009 Accepted: 5 May 2010 
Published: 5 May 2010
This article is available from: http://www.biomedcentral.com/1755-8794/3/15© 2010 M sko et al; licensee BioMed Central Ltd. is an Open Access article distribut d under th  terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Medical G nomic 2010, 3:15
Mesko et al. BMC Medical Genomics 2010, 3:15
http://www.biomedcentral.com/1755-8794/3/15
Page 12 of 1313. Steinbach D, Schramm A, Eggert A, Onda M, Dawczynski K, Rump A, 
Pastan I, Wittig S, Pfaffendorf N, Voigt A, et al.: Identification of a set of 
seven genes for the monitoring of minimal residual disease in pediatric 
acute myeloid leukemia.  Clin Cancer Res 2006, 12(8):2434-2441.
14. Schobesberger M, Baltzer A, Oberli A, Kappeler A, Gugger M, Burger H, 
Jaggi R: Gene expression variation between distinct areas of breast 
cancer measured from paraffin-embedded tissue cores.  BMC Cancer 
2008, 8:343.
15. Swingler TE, Waters JG, Davidson RK, Pennington CJ, Puente XS, Darrah C, 
Cooper A, Donell ST, Guile GR, Wang W, et al.: Degradome expression 
profiling in human articular cartilage.  Arthritis Res Ther 2009, 11(3):R96.
16. Kosa JP, Balla B, Kiss J, Podani J, Takacs I, Lazary A, Nagy Z, Bacsi K, Karsai A, 
Speer G, et al.: Postmenopausal expression changes of immune system-
related genes in human bone tissue.  J Clin Immunol 2009, 
29(6):761-768.
17. Hosack DA, Dennis G Jr, Sherman BT, Lane HC, Lempicki RA: Identifying 
biological themes within lists of genes with EASE.  Genome Biol 2003, 
4(10):R70.
18. Dudley JT, Tibshirani R, Deshpande T, Butte AJ: Disease signatures are 
robust across tissues and experiments.  Mol Syst Biol 2009, 5:307.
19. Batliwalla FM, Baechler EC, Xiao X, Li W, Balasubramanian S, Khalili H, 
Damle A, Ortmann WA, Perrone A, Kantor AB, et al.: Peripheral blood gene 
expression profiling in rheumatoid arthritis.  Genes Immun 2005, 
6(5):388-397.
20. Barnes MG, Aronow BJ, Luyrink LK, Moroldo MB, Pavlidis P, Passo MH, 
Grom AA, Hirsch R, Giannini EH, Colbert RA, et al.: Gene expression in 
juvenile arthritis and spondyloarthropathy: pro-angiogenic ELR+ 
chemokine genes relate to course of arthritis.  Rheumatology (Oxford) 
2004, 43(8):973-979.
21. Gu J, Marker-Hermann E, Baeten D, Tsai WC, Gladman D, Xiong M, Deister 
H, Kuipers JG, Huang F, Song YW, et al.: A 588-gene microarray analysis of 
the peripheral blood mononuclear cells of spondyloarthropathy 
patients.  Rheumatology (Oxford) 2002, 41(7):759-766.
22. Bruneau N, Richard S, Silvy F, Verine A, Lombardo D: Lectin-like Ox-LDL 
receptor is expressed in human INT-407 intestinal cells: involvement in 
the transcytosis of pancreatic bile salt-dependent lipase.  Mol Biol Cell 
2003, 14(7):2861-2875.
23. Dwinell MB, Eckmann L, Leopard JD, Varki NM, Kagnoff MF: Chemokine 
receptor expression by human intestinal epithelial cells.  
Gastroenterology 1999, 117(2):359-367.
24. Nagaishi T, Chen Z, Chen L, Iijima H, Nakajima A, Blumberg RS: CEACAM1 
and the regulation of mucosal inflammation.  Mucosal Immunol 2008, 
1(Suppl 1):S39-42.
25. Fireman E, Kraiem Z, Sade O, Greif J, Fireman Z: Induced sputum-
retrieved matrix metalloproteinase 9 and tissue metalloproteinase 
inhibitor 1 in granulomatous diseases.  Clin Exp Immunol 2002, 
130(2):331-337.
26. Garg P, Vijay-Kumar M, Wang L, Gewirtz AT, Merlin D, Sitaraman SV: Matrix 
metalloproteinase-9-mediated tissue injury overrides the protective 
effect of matrix metalloproteinase-2 during colitis.  Am J Physiol 
Gastrointest Liver Physiol 2009, 296(2):G175-184.
27. Gonsky R, Deem RL, Targan SR: Distinct Methylation of IFNG in the Gut.  J 
Interferon Cytokine Res 2009, 29(7):407-414.
28. Hendel J, Nielsen OH: Expression of cyclooxygenase-2 mRNA in active 
inflammatory bowel disease.  Am J Gastroenterol 1997, 92(7):1170-1173.
29. Rottman JB, Smith TL, Ganley KG, Kikuchi T, Krueger JG: Potential role of 
the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 
in the pathogenesis of psoriasis vulgaris.  Lab Invest 2001, 81(3):335-347.
30. Koczan D, Drynda S, Hecker M, Drynda A, Guthke R, Kekow J, Thiesen HJ: 
Molecular discrimination of responders and nonresponders to anti-
TNF alpha therapy in rheumatoid arthritis by etanercept.  Arthritis Res 
Ther 2008, 10(3):R50.
31. Voort R van der, van Lieshout AW, Toonen LW, Sloetjes AW, Berg WB van 
den, Figdor CG, Radstake TR, Adema GJ: Elevated CXCL16 expression by 
synovial macrophages recruits memory T cells into rheumatoid joints.  
Arthritis Rheum 2005, 52(5):1381-1391.
32. Yang MH, Wu FX, Xie CM, Qing YF, Wang GR, Guo XL, Tang Z, Zhou JG, 
Yuan GH: Expression of CC chemokine ligand 5 in patients with 
rheumatoid arthritis and its correlation with disease activity and 
medication.  Chin Med Sci J 2009, 24(1):50-54.
33. Kehlen A, Pachnio A, Thiele K, Langner J: Gene expression induced by 
interleukin-17 in fibroblast-like synoviocytes of patients with 
rheumatoid arthritis: upregulation of hyaluronan-binding protein TSG-
6.  Arthritis Res Ther 2003, 5(4):R186-192.
34. Zuo XX, Zhou YO, Gong YH, Wang YP, Tang DL, Xiao XZ: [Expression of 
high mobility group box chromosomal protein 1 in peripheral blood of 
patients with rheumatoid arthritis].  Zhonghua Nei Ke Za Zhi 2007, 
46(7):547-550.
35. Zini N, Lisignoli G, Solimando L, Bavelloni A, Grassi F, Guidotti L, Trimarchi 
C, Facchini A, Maraldi NM: IL1-beta and TNF-alpha induce changes in 
the nuclear polyphosphoinositide signalling system in osteoblasts 
similar to that occurring in patients with rheumatoid arthritis: an 
immunochemical and immunocytochemical study.  Histochem Cell Biol 
2003, 120(3):243-250.
36. Schulze-Koops H, Davis LS, Kavanaugh AF, Lipsky PE: Elevated cytokine 
messenger RNA levels in the peripheral blood of patients with 
rheumatoid arthritis suggest different degrees of myeloid cell 
activation.  Arthritis Rheum 1997, 40(4):639-647.
37. Alexander RJ, Panja A, Kaplan-Liss E, Mayer L, Raicht RF: Expression of 
protooncogene-encoded mRNA by colonic epithelial cells in 
inflammatory bowel disease.  Dig Dis Sci 1996, 41(4):660-669.
38. Pouw Kraan TC van der, Zwiers A, Mulder CJ, Kraal G, Bouma G: Acute 
experimental colitis and human chronic inflammatory diseases share 
expression of inflammation-related genes with conserved Ets2 binding 
sites.  Inflamm Bowel Dis 2009, 15(2):224-235.
39. Haas SL, Abbatista M, Brade J, Singer MV, Bocker U: Interleukin-18 serum 
levels in inflammatory bowel diseases: correlation with disease activity 
and inflammatory markers.  Swiss Med Wkly 2009, 139(9-10):140-145.
40. Mitsuyama K, Sata M, Rose-John S: Interleukin-6 trans-signaling in 
inflammatory bowel disease.  Cytokine Growth Factor Rev 2006, 
17(6):451-461.
41. Hitchon CA, Danning CL, Illei GG, El-Gabalawy HS, Boumpas DT: 
Gelatinase expression and activity in the synovium and skin of patients 
with erosive psoriatic arthritis.  J Rheumatol 2002, 29(1):107-117.
42. Partsch G, Wagner E, Leeb BF, Broll H, Dunky A, Smolen JS: T cell derived 
cytokines in psoriatic arthritis synovial fluids.  Ann Rheum Dis 1998, 
57(11):691-693.
43. Chang X, Zhao Y, Sun S, Zhang Y, Zhu Y: The expression of PADI4 in 
synovium of rheumatoid arthritis.  Rheumatol Int 2009, 29(12):1411-6.
44. Li Y, Begovich AB: Unraveling the genetics of complex diseases: 
Susceptibility genes for rheumatoid arthritis and psoriasis.  Semin 
Immunol 2009, 21(6):318-27.
45. Marutsuka K, Nawa Y, Asada Y, Hara S, Kitamura K, Eto T, Sumiyoshi A: 
Adrenomedullin and proadrenomudullin N-terminal 20 peptide 
(PAMP) are present in human colonic epithelia and exert an 
antimicrobial effect.  Exp Physiol 2001, 86(5):543-545.
46. Chosa E, Hamada H, Kitamura K, Eto T, Tajima N: Increased plasma and 
joint tissue adrenomedullin concentrations in patients with 
rheumatoid arthritis compared to those with osteoarthritis.  J 
Rheumatol 2003, 30(12):2553-2556.
47. Scaife S, Brown R, Kellie S, Filer A, Martin S, Thomas AM, Bradfield PF, Amft 
N, Salmon M, Buckley CD: Detection of differentially expressed genes in 
synovial fibroblasts by restriction fragment differential display.  
Rheumatology(Oxford) 2004, 43(11):1346-1352.
48. Nukui T, Ehama R, Sakaguchi M, Sonegawa H, Katagiri C, Hibino T, Huh NH: 
S100A8/A9, a key mediator for positive feedback growth stimulation of 
normal human keratinocytes.  J Cell Biochem 2008, 104(2):453-464.
49. Wu F, Zikusoka M, Trindade A, Dassopoulos T, Harris ML, Bayless TM, Brant 
SR, Chakravarti S, Kwon JH: MicroRNAs are differentially expressed in 
ulcerative colitis and alter expression of macrophage inflammatory 
peptide-2 alpha.  Gastroenterology 2008, 135(5):1624-1635. e1624
50. Fits L Van Der, Kant M, Wel LI Van Der, Prens EP: Polymorphisms in the 
interferon regulatory factor-1 promoter are not associated with 
psoriasis and do not influence IFN-alpha-induced Th1 polarization.  J 
Interferon Cytokine Res 2007, 27(10):841-846.
51. Bucht A, Larsson P, Weisbrot L, Thorne C, Pisa P, Smedegard G, Keystone 
EC, Gronberg A: Expression of interferon-gamma (IFN-gamma), IL-10, IL-
12 and transforming growth factor-beta (TGF-beta) mRNA in synovial 
fluid cells from patients in the early and late phases of rheumatoid 
arthritis (RA).  Clin Exp Immunol 1996, 103(3):357-367.
52. Gasche C, Bakos S, Dejaco C, Tillinger W, Zakeri S, Reinisch W: IL-10 
secretion and sensitivity in normal human intestine and inflammatory 
bowel disease.  J Clin Immunol 2000, 20(5):362-370.
Mesko et al. BMC Medical Genomics 2010, 3:15
http://www.biomedcentral.com/1755-8794/3/15
Page 13 of 1353. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, 
Tilg H: Visfatin, an adipocytokine with proinflammatory and 
immunomodulating properties.  J Immunol 2007, 178(3):1748-1758.
54. Nowell MA, Richards PJ, Fielding CA, Ognjanovic S, Topley N, Williams AS, 
Bryant-Greenwood G, Jones SA: Regulation of pre-B cell colony-
enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: 
implications in the pathogenesis of rheumatoid arthritis.  Arthritis 
Rheum 2006, 54(7):2084-2095.
55. Becker KG: Comparative genetics of type 1 diabetes and autoimmune 
disease: common loci, common pathways?  Diabetes 1999, 
48(7):1353-1358.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1755-8794/3/15/prepub
doi: 10.1186/1755-8794-3-15
Cite this article as: Mesko et al., Peripheral blood gene expression patterns 
discriminate among chronic inflammatory diseases and healthy controls and 
identify novel targets BMC Medical Genomics 2010, 3:15
